Rhumbline Advisers Iovance Biotherapeutics, Inc. Transaction History

Rhumbline Advisers

  • $109 Billion
  • Q3 2024

A detailed history of Rhumbline Advisers transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 354,071 shares of IOVA stock, worth $2.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
354,071
Previous 368,800 3.99%
Holding current value
$2.88 Million
Previous $2.96 Million 12.41%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$7.28 - $11.9 $107,227 - $175,275
-14,729 Reduced 3.99%
354,071 $3.32 Million
Q2 2024

Aug 01, 2024
SELL
$7.78 - $14.19 $176,995 - $322,822
-22,750 Reduced 5.81%
368,800 $2.96 Million
Q1 2024

May 09, 2024
BUY
$7.59 - $17.47 $175,283 - $403,452
23,094 Added 6.27%
391,550 $5.8 Million
Q4 2023

Feb 08, 2024
BUY
$3.3 - $8.89 $53,753 - $144,809
16,289 Added 4.63%
368,456 $3 Million
Q3 2023

Nov 09, 2023
SELL
$4.44 - $8.79 $55,393 - $109,664
-12,476 Reduced 3.42%
352,167 $1.6 Million
Q2 2023

Aug 08, 2023
BUY
$5.36 - $9.06 $668,670 - $1.13 Million
124,752 Added 52.0%
364,643 $2.57 Million
Q1 2023

May 11, 2023
BUY
$5.53 - $8.22 $28,833 - $42,859
5,214 Added 2.22%
239,891 $1.47 Million
Q4 2022

Feb 14, 2023
SELL
$5.62 - $10.0 $13,780 - $24,520
-2,452 Reduced 1.03%
234,677 $1.5 Million
Q3 2022

Nov 10, 2022
BUY
$9.53 - $13.11 $154,243 - $212,185
16,185 Added 7.33%
237,129 $2.27 Million
Q2 2022

Aug 11, 2022
BUY
$6.38 - $18.33 $623,370 - $1.79 Million
97,707 Added 79.28%
220,944 $2.44 Million
Q1 2022

May 12, 2022
SELL
$12.38 - $19.1 $139,671 - $215,486
-11,282 Reduced 8.39%
123,237 $2.05 Million
Q4 2021

Feb 10, 2022
BUY
$16.55 - $27.63 $76,179 - $127,180
4,603 Added 3.54%
134,519 $2.57 Million
Q3 2021

Nov 12, 2021
SELL
$20.35 - $26.63 $202,217 - $264,622
-9,937 Reduced 7.11%
129,916 $3.2 Million
Q2 2021

Aug 05, 2021
BUY
$16.33 - $33.07 $44,139 - $89,388
2,703 Added 1.97%
139,853 $3.64 Million
Q1 2021

May 06, 2021
SELL
$28.67 - $52.59 $230,478 - $422,771
-8,039 Reduced 5.54%
137,150 $4.34 Million
Q4 2020

Feb 10, 2021
SELL
$28.04 - $50.26 $35,021 - $62,774
-1,249 Reduced 0.85%
145,189 $6.74 Million
Q3 2020

Nov 12, 2020
SELL
$27.75 - $36.3 $226,745 - $296,607
-8,171 Reduced 5.28%
146,438 $4.82 Million
Q2 2020

Aug 13, 2020
SELL
$27.21 - $41.0 $293,133 - $441,693
-10,773 Reduced 6.51%
154,609 $4.24 Million
Q1 2020

May 06, 2020
BUY
$19.54 - $38.85 $79,742 - $158,546
4,081 Added 2.53%
165,382 $4.95 Million
Q4 2019

Feb 05, 2020
BUY
$17.95 - $29.41 $116,639 - $191,106
6,498 Added 4.2%
161,301 $4.47 Million
Q3 2019

Oct 23, 2019
SELL
$17.99 - $26.0 $7,285 - $10,530
-405 Reduced 0.26%
154,803 $2.82 Million
Q2 2019

Aug 14, 2019
BUY
$9.78 - $24.52 $195,384 - $489,860
19,978 Added 14.77%
155,208 $3.81 Million
Q1 2019

May 01, 2019
SELL
$8.41 - $11.26 $7,215 - $9,661
-858 Reduced 0.63%
135,230 $1.29 Million
Q4 2018

Jan 31, 2019
BUY
$7.51 - $11.93 $487,241 - $774,006
64,879 Added 91.11%
136,088 $1.2 Million
Q3 2018

Nov 07, 2018
SELL
$11.25 - $17.7 $58,668 - $92,305
-5,215 Reduced 6.82%
71,209 $801,000
Q2 2018

Aug 06, 2018
BUY
$12.45 - $16.95 $68,039 - $92,631
5,465 Added 7.7%
76,424 $978,000
Q1 2018

May 02, 2018
BUY
$8.1 - $19.5 $123,452 - $297,199
15,241 Added 27.35%
70,959 $1.2 Million
Q4 2017

Feb 09, 2018
SELL
$6.65 - $9.25 $55,507 - $77,209
-8,347 Reduced 13.03%
55,718 $446,000
Q3 2017

Nov 06, 2017
BUY
$4.45 - $8.55 $285,089 - $547,755
64,065
64,065 $497,000

Others Institutions Holding IOVA

# of Institutions
313
Shares Held
241M
Call Options Held
3.77M
Put Options Held
1.7M
View Full List

About IOVANCE BIOTHERAPEUTICS, INC.

IOVA Quotes by TradingView
  • Ticker IOVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 157,800,992
  • Market Cap $1.28B
  • Description
  • Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...
More about IOVA
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email